After a median follow-up period of 4.0 years after disease progression , patients with p16-positive OPC had significantly improved survival rates compared with p16-negative patients ( 2-year OS , 54.6 % v 27.6 % ; median , 2.6 v 0.8 years ; P < .001 ) .